Key Takeaways Pfizer will report Q3 results on Nov. 4, with investors watching the performance of key non-oncology drugs.Eliquis sales likely climbed, driven by higher demand trends globally.Abrysvo demand was likely limited by RSV guidance, while Xeljanz and Enbrel sales likely declined.Pfizer (PFE) is due to report third-quarter 2025 results on Nov. 4. All eyes will be on sales of Pfizer’s oncology drugs, which account for more than 25% of the company’s total revenues. Pfizer’s key oncology drugs are Ibra ...

"Our goal is to make healthy hydration not just convenient, but inspiring," said Jeff Schoon, President of Zurn Elkay. "With Liv EZ, we want to help families enjoy fresh, commercial-grade filtered water anywhere in their home, without compromise or the hassle of single-use bottles and bulky jugs. It's hydration that fits their lifestyle, beautifully." Remodel for Life, Not Just for LooksForget countertop clutter, fridge filters and single-use plastic bottles. Liv EZ Built-In Filtered Water Dispenser is as s ...

A group of companies including Exxon Mobil (NYSE:XOM) and BlackRock's (NYSE:BLK) Global Infrastructure Partners have joined forces to develop a new way to measure carbon emissions of the products they make, buy and finance, Bloomberg reported Monday. The group, which also ...

Crude Value Insights offers you an investing service and community focused on oil and natural gas. We focus on cash flow and the companies that generate it, leading to value and growth prospects with real potential.Subscribers get to use a 50+ stock model account, in-depth cash flow analyses of E&P firms, and live chat discussion of the sector.Sign up today for your two-week free trial and get a new lease on oil & gas! ...

Key Takeaways HQY launches GLP-1 telehealth platform, enabling seamless HSA payments for high-cost medications. HQY's Direct HSA enrollment taps ACA changes, expanding eligibility to 7M Americans by 2026. New initiatives strengthen HQY's ecosystem, driving growth in healthcare affordability and HAS. HealthEquity (HQY) recently unveiled two major consumer-focused initiatives — an integrated telehealth platform for GLP-1 medications and a direct HSA enrollment solution. The launch reflects a strategic respons ...

Key Takeaways Embraer deal highlights growing demand for next-generation, fuel-efficient aircraft.The E195-E2 offers 29% lower fuel use and seats up to 146 passengers with a 3,000-mile range.ERJ's backlog hit $13.1 billion in Q2 2025, reflecting strong commercial aviation demand.Embraer S.A. (ERJ) recently secured an order from TrueNoord to supply 20 of its E195-E2 aircraft, with an option to deliver 20 more E195-E2 aircraft and up to 10 E175-E1 aircraft. The deliveries support TrueNoord’s mission to offer ...

Key Takeaways DefenCath is CRMD's main growth driver, launched across inpatient and outpatient settings in 2024.DefenCath's sales in Q3 are expected to have been driven by strong uptake in the U.S. market.Melinta's $300M acquisition brings seven drugs, expanding CRMD's hospital and infection care portfolio.CorMedix’s (CRMD) DefenCath (Taurolidine + Heparin) is its lead marketed product and the primary revenue driver for the company. The FDA approved DefenCath in late 2023 as the first and only antimicrobial ...

Key Takeaways NextDecade approved the final investment decision for Train 5 at the Rio Grande LNG project.NEXT secured $6.7B in committed financing through debt, equity, and investor partnerships.Long-term LNG offtake deals with EQT, JERA, and ConocoPhillips back the Train 5 expansion.NextDecade Corporation (NEXT) , a U.S.-based liquefied natural gas (LNG) operator, announced that it has taken a positive final investment decision on Train 5 of the Rio Grande LNG project in Brownsville, TX. Additionally, NEX ...

Key Takeaways AbbVie's oncology segment is projected to reach $1.71B in Q3 sales, up nearly 2% from last year.Strong Venclexta, Epkinly and Elahere sales may balance ongoing weakness in Imbruvica.New lung cancer drug Emrelis, approved in May, is expected to contribute modest early sales.AbbVie (ABBV) has built a substantial oncology franchise in recent years. Initially anchored by blood cancer drugs Imbruvica and Venclexta, the company has expanded its offerings into solid tumors. Its latest offerings inclu ...

Key Takeaways PACB announced innovations to its Revio and Vega platforms, centered on SPRQ-Nx sequencing chemistry.PACB's SPRQ-Nx boosts efficiency with more runs per system and reduced waste.PacBio's Revio with SPRQ-Nx enables low-cost long-read genomes for population-scale research.Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, announced innovations to its Revio and Vega platforms last week. The innovations are expected to lower sequencing costs, add new multiomic capabilities ...